Despite Lifecome BiochemistryLtd's revenue growth, its P/S ratio isn't rising, possibly due to market expectations of future revenue performance tapering off. Investors may face disappointment if the company's revenue growth doesn't keep up with the industry.

Despite strong revenue, Lifecome Biochemistry's growth rates lag behind the industry's predicted 842% growth. Investors may face disappointment if P/S falls in line with recent growth rates. The company's poor three-year revenue trends aren't resulting in a lower P/S as expected. Without significant medium-term performance improvement, preventing P/S ratio decline will be challenging.

The company's EBIT loss of CN¥127m and the liabilities do not inspire confidence in the company's use of debt. The balance sheet appears strained, and the stock is considered very risky.